Trethera Secures $3 Million NIH Grant to Advance TRE-515 for Lupus Treatment

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

August 20, 2025 | Wednesday | News
HUTCHMED Completes Patient Enrollment in Phase III SANOVO Study of ORPATHYS® and TAGRISSO® in First-Line NSCLC

HUTCHMED (China) Limited  announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRI...

August 20, 2025 | Wednesday | News
Qihan Biotech Receives FDA Clearance to Begin U.S. Trial of Universal CAR-T Therapy for Refractory Lupus

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to...

August 19, 2025 | Tuesday | News
Atropos Health and Novartis Partner to Harness AI for Faster Rare Disease Diagnosis

-Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, announced a collaboration wit...

August 19, 2025 | Tuesday | News
Ascentage Pharma Receives FDA and EMA Clearance for Global Phase III Trial of Lisaftoclax in Higher-Risk MDS

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and c...

August 18, 2025 | Monday | News
CILA Therapeutics Secures NIH Grant to Advance CIL-Key™ Platform for Inhaled RNA Delivery in Lung Diseases

-CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Insti...

August 15, 2025 | Friday | News
Cytiva and Culture Biosciences Partner to Deliver Seamless Scale-Up with Stratyx 250 Bioreactor

  Cytiva has deepened its partnership with Culture Biosciences, introducing the Stratyx 250 process development bioreactor. Speaking to BioPharma Boa...

August 18, 2025 | Monday | News
Rapid Micro Biosystems Secures $45 Million Loan Facility to Accelerate Global Growth of Growth Direct® System

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company prov...

August 14, 2025 | Thursday | News
MAIA Biotechnology Secures European Patent for Next-Generation Telomere-Targeting Cancer Therapies

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...

August 14, 2025 | Thursday | News
Bayer and Kumquat Biosciences Partner to Develop First-in-Class KRAS G12D Inhibitor for Hard-to-Treat Cancers

Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancr...

August 13, 2025 | Wednesday | News
Fosun Pharma Grants Global Rights (Ex-China) for Innovative Respiratory Drug XH-S004 to Expedition Therapeutics

Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics ...

August 12, 2025 | Tuesday | News
Junshi Biosciences’ sNDA for Toripalimab Plus Disitamab Vedotin in HER2-Expressing Urothelial Carcinoma Accepted by China’s NMPA

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...

August 11, 2025 | Monday | News
OmniAb CEO Matt Foehr Highlights Robust Partner Growth and Innovation Momentum in Q2 2025 Results

OmniAb, Inc. reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. “Our...

August 07, 2025 | Thursday | Company results
Exact Sciences Secures Exclusive U.S. Rights to Freenome’s Blood-Based Colorectal Cancer Screening Tests

Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome sub...

August 07, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close